本文選題：ZHJ-MAPCs + 細(xì)胞傳代　； 參考：《第一軍醫(yī)大學(xué)》2005年碩士論文

【摘要】：治療終末期肝病最有效的方法之一就是原位肝移植(orthotopic liver transplantation,OLT),然而,由于供體的缺乏、免疫排斥和高額費(fèi)用等問(wèn)題,OLT的廣泛應(yīng)用受到了限制。肝細(xì)胞移植(hepatocytes transplantation HCT)經(jīng)過(guò)近30年的發(fā)展,正由動(dòng)物實(shí)驗(yàn)向臨床過(guò)渡,初步結(jié)果顯示,肝細(xì)胞移植在急慢性肝衰竭和遺傳代謝性肝病方面具有很好的應(yīng)用前景,但同樣面臨肝細(xì)胞來(lái)源有限,排斥反應(yīng)等問(wèn)題的困擾。雜交型生物人工肝(Hybrid bioartificial liver,HBAL)治療可以使終末期肝病病人橋接(bridge)肝移植,而且由于肝細(xì)胞具有強(qiáng)大的再生能力,臨時(shí)應(yīng)用生物人工肝也可以暫時(shí)代償肝功能,促進(jìn)肝細(xì)胞再生,部分患者肝功能完全恢復(fù)正常。但作為HBAL核心生物材料的肝細(xì)胞來(lái)源問(wèn)題未得到根本解決,使HBAL的臨床應(yīng)用遠(yuǎn)未達(dá)到理論上的預(yù)期效果。研究證明人骨髓來(lái)源的多能成體祖細(xì)胞(Multipotent adult progenitor cells from bone marrow,MAPCs)具有向肝樣細(xì)胞分化的潛能,由于其具有易于增殖、調(diào)控、供源豐富、容易獲取、有自體供源避免免疫排斥等優(yōu)點(diǎn),有望成為理想的組織工程細(xì)胞來(lái)源。本課題組前期實(shí)驗(yàn)通過(guò)密度梯度離心—貼壁培養(yǎng)篩選—免疫磁性雙陰性分選(magnetic activated cell sorting,MACS)三個(gè)步驟高效率地純化分選出骨髓間充質(zhì)干細(xì)胞(mesenchymal stem cells,MSCs)亞群MAPCs(CD45~-,GlyA~-),并將之命名為ZHJ-MAPCs(Zhujiang-MAPCs)。通過(guò)改良細(xì)胞培養(yǎng)基等方法,我們建立了ZHJ-MAPCs的傳代培養(yǎng)技術(shù)(結(jié)果尚未發(fā)表)。
[Abstract]:One of the most effective methods for the treatment of end-stage liver disease is in situ orthotopic liver transplantation (OLT). However, the wide application of OLT is limited due to the lack of donor, immune rejection and high cost. The development of hepatocytes transplantation HCT (hepatocytes transplantation HCT) is being conducted by animal experiments for nearly 30 years. The preliminary results show that hepatocyte transplantation has a good application prospect in acute and chronic liver failure and genetic metabolic liver disease, but it also faces problems such as limited source of hepatocyte and rejection. Hybrid bioartificial liver (HBAL) can bridge patients with end-stage liver disease (Bridg E) liver transplantation, and because of the powerful regeneration ability of liver cells, temporary application of biological artificial liver can also temporarily compensate liver function, promote hepatocyte regeneration, and restore normal liver function in some patients. However, the liver cell source problem of HBAL core biomaterial has not been fundamentally solved, so that the clinical application of HBAL is far from the theory. Multipotent adult progenitor cells from bone marrow, MAPCs) has the potential to differentiate into hepatocyte like cells. It is expected to be an ideal tissue because it has the advantages of easy proliferation, regulation, rich source, easy access, and autologous source to avoid immune rejection. The project cell source. In the preliminary experiment, we purified the bone marrow mesenchymal stem cells (mesenchymal stem cells, MSCs) subgroup MAPCs (CD45~-, GlyA~-) by the three steps of the density gradient centrifugation - adherent culture screening - magnetic activated cell sorting (MACS). PCs (Zhujiang-MAPCs). By means of improved cell culture medium, we have established ZHJ-MAPCs subculture Technology (the result has not yet been published).

【學(xué)位授予單位】：第一軍醫(yī)大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2005
【分類號(hào)】：R329.2;R657.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 李秀森,郭子寬,楊靖清,劉曉丹,侯春梅,唐佩弦,毛寧;骨髓間充質(zhì)干細(xì)胞的生物學(xué)特性[J];解放軍醫(yī)學(xué)雜志;2000年05期

2 唐望先,張國(guó),王俊平,張文英;流式細(xì)胞術(shù)動(dòng)態(tài)檢測(cè)肝大部切除后再生相關(guān)因子的實(shí)驗(yàn)研究[J];同濟(jì)醫(yī)科大學(xué)學(xué)報(bào);2001年04期

3 蒯小玲,蕭樹(shù)東,叢笑倩,李秀蘭;小鼠胚胎干細(xì)胞誘導(dǎo)為肝細(xì)胞的研究[J];胃腸病學(xué);2003年01期

4 薛國(guó)柱,劉冰艷,陳蘆斌,高毅,楊繼震;人肝細(xì)胞系生物功能篩選測(cè)定[J];外科理論與實(shí)踐;2002年02期

5 陳蕾蕾,陳軍浩,孫雪梅,施廣飛;熒光染料CFSE作為細(xì)胞標(biāo)記的特性研究[J];細(xì)胞與分子免疫學(xué)雜志;2004年02期

6 何念海,趙文利,王宇明;人胎兒骨髓間充質(zhì)干細(xì)胞來(lái)源的類肝細(xì)胞的分子生物學(xué)鑒定[J];世界華人消化雜志;2004年08期

7 陳柯,高毅,楊繼震;原代豬肝細(xì)胞培養(yǎng)體系及培養(yǎng)模式的初步探討[J];中華肝膽外科雜志;2001年04期

，

本文編號(hào)：1800208